After only 16 weeks of existence, foetuses hear and respond to music as long as it is emitted from their mother’s vagina. Foetuses respond to this stimulus by opening their mouths and pulling their tongues out as far as possible, making vocalisation movements – prior to the acquisition of language.
This is the main conclusion of the study conducted by the team of Institut Marquès, which boasts the collaboration of Alberto Prats, Professor of Anatomy and Human Embryology of the Faculty of Medicine of the University of Barcelona.
The study, entitled “Foetal facial expression in response to intravaginal music emission”, is published this week in the journal Ultrasound of the British Medical Ultrasound Society (BMUS).
According to Dr. Marisa López-Teijón, the Head of Assisted Reproduction at Institut Marquès and the principal researcher and author of the clinical study: “We have discovered that the formula for foetuses to hear like us is to emit music from the mother’s vagina. They barely hear the sound that reaches them through their mother’s abdomen: the soft tissues of the abdomen and the inside of the mother’s body absorb the soundwaves”.
To view the multimedia release go to:
http://www.multivu.com/players/English/7647351-how-foetuses-hear-musical-stimuli/
Eli Lilly and Company (NYSE: LLY) will commemorate its 140th anniversary today with activities at Lilly locations worldwide, including a ceremony to unveil a statue dedicated to founder Colonel Eli Lilly at global headquarters in Indianapolis.
Over 14 decades, the organization has contributed more than 100 medicines and significant medical advances, such as the first commercially available insulin, manufacturing and global distribution of the Salk polio vaccine and mental health breakthroughs such as anti-depressant Prozac® (fluoxetine). Today Lilly continues to progress its most robust pipeline in history with dozens of potential new medicines in mid- to late-stage development for cancer, diabetes, autoimmune disease, pain and Alzheimer’s disease.
“As Lilly celebrates 140 years, we’re keeping the vision of our founder alive – from our dedication in the lab to our impact in the community,” said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer, who began his career at Lilly as a chemist in 1979. “Colonel Eli Lilly started this company to put science to work fighting disease and encouraged his successors to ‘take what you find here and make it better and better.’ That vision pushes us daily to honor Colonel Lilly’s legacy and continue in our quest to discover new medicines to help make life better.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7809951-eli-lilly-and-company-140th-anniversary/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide.
This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
The American Association for Cancer Research (AACR) today released its annual Cancer Progress Report highlighting how federally funded research discoveries are fueling the development of new and even more effective ways to prevent, detect, diagnose, and treat cancer.
To view the multimedia release go to:
https://www.multivu.com/players/English/8385551-aacr-cancer-progress-report-2018/
International Medical Group® (IMG®), a leader in global benefits and assistance services, today announced the company’s new corporate branding and logo.
“After more than 25 years as a leader in the industry, it was time to refresh our brand identity,” said IMG President and CEO Todd A. Hancock. “The new logo reflects IMG’s focus on providing a foundation of security, health and well-being for our members while they’re away from home.”
IMG’s constituents — members, intermediaries, partners and employees — are represented by the logo’s four inverted angles. These angles are symbolic of a flock of Arctic terns, birds whose annual migration is the longest of any animal in the world.
To view the multimedia release go to:
http://www.multivu.com/players/English/7950351-international-medical-group-rebrands/
CVS Health (NYSE:CVS), the nation’s largest pharmacy innovation company, today announced Be The First, a five-year $50 million initiative to help deliver the nation’s first tobacco-free generation. Through this initiative, which is funded through CVS Health and the CVS Health Foundation, the company is extending its commitment to help people lead tobacco-free lives. Recognizing that tobacco use is the leading preventable cause of disease and death in the United States and that youth use of some tobacco products is on the rise, Be The First comprises comprehensive education, advocacy, tobacco control and healthy behavior programming in partnership with organizations uniquely positioned to tackle this public health challenge.
“We are at a critical moment in our nation’s efforts to end the epidemic of tobacco use that continues to kill more people than any other preventable cause of death, and threatens the health and well-being of our next generation,” said Troyen A. Brennan, M.D., M.P.H., and Chief Medical Officer for CVS Health. “Ensuring our youth stay tobacco-free requires increased education and awareness of healthy behaviors. We’re partnering with experts across the public health community who have established best practices to help prevent tobacco use. And, by establishing more public-private partnerships to implement these strategies more aggressively, we can help increase the number of people leading tobacco-free lives and move us one step closer to delivering the first tobacco-free generation.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7775151-cvs-health-be-the-first/
Losing weight and being healthier are at the top of everyone’s New Year’s resolutions. But, despite the best intentions, work, kids, and social events often push lifestyle changes to the bottom of the list. While many are familiar with type 2 diabetes, fewer are aware of prediabetes, a serious health condition that affects 86 million Americans (more than 1 in 3) and often leads to type 2 diabetes. People with prediabetes have higher than normal blood glucose (sugar) levels, but not high enough yet to be diagnosed with type 2 diabetes.
To raise awareness and help people with prediabetes know where they stand and how to prevent type 2 diabetes, the American Diabetes Association (ADA), the American Medical Association (AMA), and the Centers for Disease Control and Prevention (CDC) have partnered with the Ad Council to launch the first national public service advertising (PSA) campaign about prediabetes. The PSA campaign, featuring first-of-its-kind communications techniques, was developed pro bono by Ogilvy & Mather New York for the Ad Council.
Nearly 90 percent of people with prediabetes don’t know they have it and aren’t aware of the long-term risks to their health, including type 2 diabetes, heart attack, and stroke. Current trends suggest that, if not treated, 15 to 30 percent of people with prediabetes will develop type 2 diabetes within five years. The good news is that prediabetes often can be reversed through weight loss, diet changes and increased physical activity. Diagnosis is key: research shows that once people are aware of their condition, they are much more likely to make the necessary lifestyle changes.
To view the multimedia release go to:
http://www.multivu.com/players/English/7731551-ad-council-prediabetes-psa/
Dornier MedTech® America, a global medical device company and the pioneer of Extracorporeal Shock Wave Lithotripsy (ESWL®), has received FDA clearance to market the Delta® III. This is the latest generation of the world’s best-selling and most clinically cited lithotripter, the Delta II.
To view the multimedia release go to:
https://www.multivu.com/players/English/8134451-dornier-medtech-delta-iii-kidney-stone-lithotripter/
https://nationlife.net/enjoy-eating-without-the-fear-of-choking-with-lifevac-review/
LifeVac is a patented life-saving device that is proven to be the most effective way to help a child or adult during a choking emergency.
Place LifeVac over the mouth and nose to create a seal. The one-way valve prevents air from pushing food or objects downward when pressed. Then simply pull to create a one-way suction to remove the lodged food or object in seconds.
LifeVac gives you peace of mind knowing you’re always prepared and your loved ones are protected – because every second matter.
Recommended by hundreds of doctors and medical professionals around the world. Over 100,000 sold in over 40 countries and counting!
Is your life or your child’s life, worth LESS than 100 bucks to you? This product is absolutely worth every penny. And I’ll be still very happy to have bought it, even if I don’t ever get to use it. I know it is there if I ever need it. This thing is absolutely fantastic. I’ve practiced a few times and from what I saw, it can very well save a life, in those critical few minutes you have, before the person becomes so deprived from oxygen and ultimately dies. Very easy to use. I’m grateful for it.
Always Be Prepared. Get LifeVac Today.
Dentro de las más de 50 propuestas de estudios de investigación, el estudio sobre ácidos grasos de omega 3 en pacientes hospitalizados que requieren nutrición parenteral y presentan complicaciones relacionadas con insuficiencias intestinales propuesto por la investigadora médica, la Dra. Aurora Serralde Zúñiga, ganó el primer subsidio para la investigación sobre nutrición parenteral en América Latina (Parenteral Nutrition Research Grant Latin America).
To view the multimedia release go to:
https://www.multivu.com/players/Spanish/8451051-ganadora-del-subsidio-fresenius-kabi/
Solta Medical's novel addition to its aesthetic device solutions, the Clear + Brilliant pélo™ laser, offers personalized results with groundbreaking laser hair removal [LHR] technology to make it fast and simple with minimal pain for anyone to get rid of unwanted hair.
The Clear + Brilliant pélo™ laser provides a highly effective treatment in a short amount of time due to its innovative linear scanning technology and the largest treatment window in the market. A full back takes only 8-12 minutes, and full legs take about 36 minutes. After 5-6 treatments, patients can see the results they want, and still have money in their pocket for the long run.
Each treatment can be customized depending on the individual's needs, and patient comfort is enhanced by minimizing pain on contact through a sapphire glass handpiece that quickly chills to 0°C. So patients and physicians can rest easy that their individual needs are met.
To view the multimedia release go to:
http://www.multivu.com/players/English/7621831-clear-brilliant-pelo-laser-hair-removal/
